Asklepios BioPharmaceutical, Inc. (AskBio)

42 articles with Asklepios BioPharmaceutical, Inc. (AskBio)

• Gene Therapy Leader Katherine High Joins AskBio as President, Therapeutics

  1/12/2021

  Asklepios BioPharmaceutical, Inc., a clinical-stage adeno-associated virus gene therapy company and wholly owned subsidiary of Bayer AG, announced that Katherine High, MD, has joined the company in the newly formed role of President, Therapeutics and will also serve on its Board of Directors.

• AskBio CSO Jude Samulski Named 2020 Business Person of the Year by Triangle Business Journal

  12/11/2020

  Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that its President and Chief Scientific Officer, Jude Samulski, PhD, has been honored as Triangle Business Journal’s (TBJ) 2020 Business Person of the Year. “My passion to help people is reflected in the work we do every day to bring much-needed treatments to patients and their families who ar

• AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic AcidemiaGene therapy MMA-101 has obtained both orphan drug designation and rare pediatric disease designation from the FDA

  11/19/2020

  Asklepios BioPharmaceutical, Inc. and Selecta Biosciences, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia due to methylmalonyl-CoA mutase gene mutations.

• AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic AcidemiaGene therapy MMA-101

  11/19/2020

  Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia (MMA) due to methylmalonyl-CoA mutase (MMUT) gene mutations. MMA-101 previously received rare pediatric disease de

• Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene Therapy

  10/26/2020

  Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need

• 

  Bayer Acquires AskBio for Up to $4 Billion to Expand Gene Therapy Platform

  10/26/2020

  Bayer is paying $2 billion upfront for AskBio's AAV-based gene therapy pipeline of treatments for Pompe disease, among others, and could pay an additional $2 billion in potential milestones.
• 

  BioSpace Movers & Shakers, Sept. 18

  9/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Kellie Sears Named AskBio Chief Human Resources Officer

  9/16/2020

  Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Kellie Sears has been appointed to its executive team as Chief Human Resources Officer. She joins AskBio from Allergan and will have responsibility for all aspects of human capital management, including talent acquisition and administration, leadership development, compensation and benefits

• AskBio CSO Jude Samulski Receives 2020 Life Sciences Award from the Triangle Business Journal

  8/24/2020

  Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that its president and chief scientific officer, Jude Samulski, PhD, has been honored as one of the Triangle Business Journal’s (TBJ) 2020 Life Sciences Award winners. The award recognizes individuals and research organizations at the forefront of innovation in the growing Triangle-area life

• AskBio CSO Jude Samulski Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine

  8/3/2020

  Asklepios BioPharmaceutical, Inc., a leading, clinical-stage adeno-associated virus gene therapy company, announced that Jude Samulski, PhD, AskBio’s President and Chief Scientific Officer, has been named to PharmaVOICE magazine’s annual list of the 100 most inspiring and entrepreneurial leaders in the life sciences industry.

• Libbie Mansell Joins AskBio as SVP Regulatory Affairs

  7/23/2020

  Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, announced today that Libbie Mansell, PhD, MBA, RAC, has joined the company as a senior vice president to lead its regulatory affairs operations. “Libbie’s career has spanned the development of small molecules and biologics. She has overseen nine global approvals for significant products, and she has created

• AAV Gene Therapy Pioneer Jude Samulski Develops Proprietary Regulated Gene Editing SystemTechnology Brings Together Benefits of AAV and CRISPR While Minimizing Negative Effects That Occur During Gene Editing

  6/23/2020

  Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Jude Samulski, PhD, President, Chief Scientific Officer and Co-founder, has been awarded an international patent application from the World Intellectual Property Organization (WO/2020/076892) for his regulated gene editing system

• AskBio Announces Appointment of Tim Trost as Chief Financial Officer

  5/19/2020

  Asklepios BioPharmaceutical , Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced the appointment of Tim Trost as Chief Financial Officer. Mr. Trost is a highly accomplished CFO with more than 25 years of experience building, managing and financing emerging life sciences companies. Prior to joining AskBio, Mr. Trost most recently served as CFO at Chimerix (NASDAQ: CMRX), w

• AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases

  4/22/2020

  Asklepios BioPharmaceutical, Inc., a leading, clinical-stage adeno-associated virus gene therapy company, announced that it has acquired BrainVectis, a Paris-based gene therapy company and French National Institute for Health and Medical Research spin-out with expertise and an intellectual property estate for the treatment of neurodegenerative disorders.

• Don Haut, PhD, Joins AskBio as Chief Business Officer

  4/7/2020

  Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Don Haut, PhD, has been appointed its Chief Business Officer to oversee business development strategy and execution. “

• AskBio Enters Research Collaboration and Licensing Agreement with University of North Carolina (UNC) for Angelman Syndrome

  3/18/2020

  Collaboration builds upon preclinical research that demonstrates potential for gene therapy to correct deficiency in UBE3A gene

• Tim Kelly Joins AskBio as President of Manufacturing to Lead AAV Vector Production for Gene Therapy

  3/12/2020

  Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced the appointment of Tim Kelly, PhD, as President of Manufacturing. He will oversee all manufacturing functions at AskBio and its Viralgen affiliate for the production of clinical- and commercial-scale AAV vectors.

• AskBio Appoints Anna Tretiakova, PhD, as Senior Vice President of Product Development

  2/19/2020

  Asklepios BioPharmaceutical, Inc., a leading clinical-stage adeno-associated virus gene therapy company, announced that it has appointed scientific leader Anna Tretiakova, PhD, as Senior Vice President of Product Development.

• AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure

  2/4/2020

  Asklepios BioPharmaceutical (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, and its NanoCor Therapeutics subsidiary today announced that the first patient has been dosed in a Phase 1 clinical trial of NAN-101. NAN-101 is a gene therapy that aims to activate protein phosphatase inhibitor 1 (I-1c) to inhibit the activity of protein phosphatase 1 (PP1), a substance that plays an important role in the development of heart failure.

• AskBio Launches AskFirst™ Patient Advocacy Program to Educate and Support Participants in Gene Therapy Clinical TrialsMatthew Alsante to Lead Program as Director of Patient Advocacy

  1/29/2020

  Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, today introduced AskFirst™, its collaborative program for patients and their families who may benefit from its advances in gene therapy research and potential curative therapies